Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

Amneal Pharmaceuticals (Nasdaq: AMRX) will be added to the S&P SmallCap 600 Index effective before market open on January 30, 2026.

Rhea-AI Summary

Amneal Pharmaceuticals (Nasdaq: AMRX) will be added to the S&P SmallCap 600 Index effective before market open on January 30, 2026. The inclusion reflects the company’s consistent operating and financial performance and places Amneal among select pharma and biotech small-cap peers.

The company said the listing may enhance visibility, broaden its investor base, and is typically associated with increased trading liquidity for affected stocks.

Positive

• Index inclusion effective January 30, 2026
• Potential liquidity boost and broader investor awareness
• Recognition of consistent performance by index screening criteria

Negative

• None.

Argus Jan 29 session

+1.15% close to close Open Argus

Details

News Market Reaction – AMRX

On Jan 29, the first trading day after this news, AMRX closed 1.15% above the previous close.

Data tracked by StockTitan Argus for the Jan 29 session.

Key Figures

2025 net revenue guidance: $3.0B–$3.1B 2025 adjusted EBITDA guidance: $675M–$685M 2025 adjusted diluted EPS guidance: $0.75–$0.80 +5 more

2025 net revenue guidance

$3.0B–$3.1B

Full-year 2025 target from 8-K filed 2026-01-13

2025 adjusted EBITDA guidance

$675M–$685M

Full-year 2025 target from 8-K filed 2026-01-13

2025 adjusted diluted EPS guidance

$0.75–$0.80

Full-year 2025 target from 8-K filed 2026-01-13

Q3 2025 net revenue

$784.5M

Quarterly revenue vs $702.5M a year ago

Q3 2025 operating income

$70.3M

Operating income vs $88.8M a year ago

Q3 2025 net income

$2.4M

Net income attributable to Amneal; $0.01 diluted EPS

Net leverage 2025 year-end est.

3.6x

Estimated as of Dec 31, 2025, improved from 3.9x

Current share price

$13.83

Pre-news price, about 1.14% below 52-week high of $13.99

Historical Context

5 past events · Latest: Jan 27

5 events

1. Jan 27

   Earnings date set

   24h Move

   +1.9%

   Company scheduled Q4 and full-year 2025 earnings release and webcast.

2. Jan 09

   R&D collaboration

   24h Move

   -1.8%

   Research collaboration and option agreement for Parkinson’s LRRK2 program KFRX06.

3. Dec 22

   FDA biosimilar OK

   24h Move

   +0.2%

   FDA approvals for two denosumab biosimilars referencing Prolia and XGEVA.

4. Dec 09

   FDA drug approval

   24h Move

   +2.0%

   FDA approval of epinephrine injection vials for U.S. hospitals and acute care.

5. Dec 05

   Clinical data update

   24h Move

   +2.4%

   Positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

s&p smallcap 600 index

1 terms

s&p smallcap 600 index financial

"it has been added to the S&P SmallCap 600® Index."

A stock market index composed of 600 U.S. companies that are relatively small in total stock value, selected to represent the small-company segment of the market. Investors and fund managers use it as a benchmark and as a way to gain broad exposure to smaller firms; think of it as a single basket or thermometer that shows how the small-company portion of the stock market is performing and helps guide portfolio allocation and risk decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600^® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026.

Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure to companies that meet disciplined criteria for market capitalization, liquidity, sector representation, and sustained profitability. Amneal’s inclusion reflects the Company’s consistent operating and financial performance and places it among a select group of pharmaceutical and biotechnology companies that meet the index’s screening requirements.

“We are pleased to be included in the S&P SmallCap 600 Index, which reflects the progress we have made executing our strategy and delivering consistent and growing financial performance,” said Tasos Konidaris, Executive Vice President and Chief Financial Officer of Amneal. “We believe this recognition enhances Amneal’s visibility within the investment community and supports the continued expansion of our investor base over time.”

Inclusion in the index is typically associated with increased trading liquidity and broader investor awareness for those seeking a more selective segment of the U.S. small-cap universe.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Amneal (AMRX) join the S&P SmallCap 600 index?

Amneal (AMRX) will join the S&P SmallCap 600 effective before market open on January 30, 2026. According to the company, the inclusion becomes effective prior to trading and will be reflected in index-owned portfolios and benchmarks.

What does the S&P SmallCap 600 inclusion mean for AMRX shareholders?

Inclusion often leads to increased trading liquidity and investor interest for AMRX. According to the company, the listing may broaden the investor base and raise the stock's visibility among small-cap managers and ETFs.

Why was Amneal (AMRX) added to the S&P SmallCap 600 index?

Amneal met the index's screening criteria for market cap, liquidity, sector representation, and profitability. According to the company, the inclusion reflects its consistent operating and financial performance meeting those standards.

Will AMRX be added to ETFs and passive funds tracking the S&P SmallCap 600?

Passive funds tracking the index typically adjust holdings to include new constituents like AMRX. According to the company, index inclusion is expected to prompt some reweighting by index-tracking ETFs and funds.

How might AMRX's trading volume react after the January 30, 2026 inclusion?

Trading volume for AMRX may increase as index funds and active managers adjust positions. According to the company, inclusion is typically associated with higher liquidity and broader investor awareness over time.